Filtered By:
Specialty: Hematology
Condition: Bleeding

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 643 results found since Jan 2013.

Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease
Discussion. OFXais were better tolerated compared to warfarin for the treatment of VTE in CKD, with lower rates of bleeding, discontinuations, and recurrent thromboembolism in a small cohort. Future prospective studies are necessary to confirm these findings.PMID:33628255 | PMC:PMC7895609 | DOI:10.1155/2021/8870015
Source: Advances in Hematology - February 25, 2021 Category: Hematology Authors: Tania Ahuja Kelly Sessa Cristian Merchan John Papadopoulos David Green Source Type: research

Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases
We report the cases relating to three patients in concomitant therapy with Ibrutinib and Dabigatran.
Source: Blood Coagulation and Fibrinolysis - February 11, 2021 Category: Hematology Tags: CASE REPORTS Source Type: research

Efficacy and safety of abciximab versus tirofiban in addition to ticagrelor in STEMI patients undergoing primary percutaneous intervention.
The objectives were to assess the efficacy and safety of abciximab versus tirofiban in patients with ST-elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) and pretreated with ticagrelor, and to identify independent predictor factors of efficacy, bleeding and platelet drop. Three hundred sixty-two patients were divided by GPI administered. Clinical, laboratory, angiographic and outcome characteristics were compared. The primary objective was a composite efficacy endpoint (death from any cause, nonfatal myocardial infarction and nonfatal stroke) at 30 days. The seconda...
Source: Platelets - February 10, 2021 Category: Hematology Tags: Platelets Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Pulmonary embolism (PE) ranks as the third most common cardiovascular death after coronary artery disease and stroke [1] and, the second leading cause of death after cancer among cancer patients [2]. Acute Kidney Injury (AKI), defined as an abrupt decrease in kidney function, is associated with adverse short-term and long-term outcomes even in the case of mild and reversible AKI [3]. One-third of patients with PE develop AKI and are at increased risk for bleeding and mortality compared with patients without AKI [4].
Source: Thrombosis Research - January 14, 2021 Category: Hematology Authors: Martin Murgier, L éa Fouillet, Edouard Ollier, Adel Merah, Nathalie Moulin, Sandrine Accassat, Cécile Duvillard, Elodie De Magalhaes, Patrick Mismetti, Manuel Monreal, Laurent Bertoletti Tags: Letter to the Editors-in-Chief Source Type: research

Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus
AbstractLeft ventricular (LV) thrombus is a complication of acute endomyocardial injury and chronic ventricular wall hypokinesis, resulting in increased risk of thromboembolic complications. Observational studies support the general safety and efficacy of warfarin for this indication. Limited data exists regarding the use of direct oral anticoagulants (DOACs) for LV thrombus. This retrospective cohort study sought to compare the incidence of thromboembolic events, bleeding rates, and blood product administration in patients receiving a DOAC versus warfarin. A total of 949 patients met inclusion, 180 (19%) received a DOAC a...
Source: Journal of Thrombosis and Thrombolysis - January 9, 2021 Category: Hematology Source Type: research

Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases.
Authors: Harbi MH, Smith CW, Nicolson PLR, Watson SP, Thomas MR Abstract Antiplatelet medications comprise the cornerstone of treatment for diseases that involve arterial thrombosis, including acute coronary syndromes (ACS), stroke and peripheral arterial disease. However, antiplatelet medications may cause bleeding and, furthermore, thrombotic events may still recur despite treatment. The interaction of collagen with GPVI receptors on the surface of platelets has been identified as one of the major players in the pathophysiology of arterial thrombosis that occurs following atherosclerotic plaque rupture. Promising...
Source: Platelets - December 15, 2020 Category: Hematology Tags: Platelets Source Type: research

Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: A nationwide population-based study.
CONCLUSIONS: Age is an important determinant of ischemic stroke and composite outcome in intermediate-risk AF patients. The benefit of OAC therapy for these AF patients appears to have an age threshold (age ≥ 55 years). PMID: 33307565 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - December 11, 2020 Category: Hematology Authors: Choi SY, Kim MHH, Lee KM, Cho YR, Park JS, Yun SC, Lip GY Tags: Thromb Haemost Source Type: research

Use of direct oral anticoagulants in cerebral venous thrombosis: a systematic review
We are here to review the efficacy and safety of direct oral anticoagulants (DOACs) in the treatment of Cerebral Venous Thrombosis (CVT). A search strategy was developed with a research librarian. All published articles including trials, studies, case series, and case reports were reviewed from NCBI/PubMed up to May 2019 by two independent reviewers. A total of 11 studies were identified, which included 70 patients with CVT on DOACs. After 6 months follow-up more than 86.7% of these patients had a good outcome on the Modified Rankin Scale (mRS) of 0--1 at 6 months and no recurrence of venous thromboembolic events (VTE) at ...
Source: Blood Coagulation and Fibrinolysis - November 17, 2020 Category: Hematology Tags: REVIEW ARTICLE Source Type: research

Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data
AbstractLong-term follow-up data of left atrial appendage (LAA) occlusion in patients with atrial fibrillation (AF) are sparse. To address these data gaps, we analysed the 4-year outcomes of AF patients following LAA occlusion. The was a retrospective cohort study of high-risk patients with AF who underwent successful implantation of the Amulet device at our center between 2014 and 2017. Study endpoints were the rate of stroke, major bleeding and all-cause mortality. We included 71 patients (35.2% females) with a median age of 78 (IQR 73 –82) years. Over a median follow-up period of 46 (IQR 19–56) months, the annual ra...
Source: Journal of Thrombosis and Thrombolysis - November 9, 2020 Category: Hematology Source Type: research

Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant
Atrial fibrillation (AF) is associated with increased risk of stroke and thromboembolism. Patients with AF have a higher incidence of renal impairment, which may influence the risks of systemic thromboembolism or bleeding. We determined how different oral anticoagulants affect plasma clot properties and whether progressive renal dysfunction affects plasma clot properties in patients on warfarin.
Source: Thrombosis Research - November 7, 2020 Category: Hematology Authors: Ahsan A. Khan, Lewis J. Hardy, Eduard Shantsila, Yee C. Lau, Helen Philippou, Gregory Y.H. Lip Source Type: research

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
AbstractNew oral anticoagulants (NOACs) is the preferred treatment in secondary prophylaxis of venous thromboembolic events (VTE). The aim of this study was to investigate possible risk factors associated with major bleeding in VTE-patients treated with NOACs. In this retrospective register-based study we screened the Swedish anticoagulation registerAuricula (during 2012.01.01 –2017.12.31) to find patients and used other national registers for outcomes. Primary endpoint was major bleeding defined as bleeding leading to hospital care. Multivariate Cox-regression analysis was used to reveal risk factors. 18 219 patients wi...
Source: Journal of Thrombosis and Thrombolysis - November 2, 2020 Category: Hematology Source Type: research

Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Semin Thromb Hemost DOI: 10.1055/s-0040-1716874Thrombotic cardiovascular disease (myocardial infarction [MI], stroke, and venous thromboembolism [VTE]) remains a major cause of death and disability. Sulodexide is an oral glycosaminoglycan containing heparan sulfate and dermatan sulfate. We conducted a systematic review and meta-analysis to determine the cardiovascular efficacy, and safety of sulodexide versus control in randomized controlled trials (RCTs). We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for RCTs reporting cardiovascular outcomes in patients receiving sulodexide versus co...
Source: Seminars in Thrombosis and Hemostasis - October 21, 2020 Category: Hematology Authors: Bikdeli, Behnood Chatterjee, Saurav Kirtane, Ajay J. Parikh, Sahil A. Andreozzi, Giuseppe M. Desai, Nihar R. Francese, Dominic P. Gibson, C Michael Piazza, Gregory Goldhaber, Samuel Z. Eikelboom, John W. Krumholz, Harlan M. Stone, Gregg W. Tags: Review Article Source Type: research

Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis
ConclusionsIn comparison to VKA, DOACs were associated with a significant reduction of the rates of thromboembolic events and major bleeding complications in patients with AF and cancer. Further studies are needed to confirm our results.
Source: Journal of Thrombosis and Thrombolysis - October 12, 2020 Category: Hematology Source Type: research